SCHEMBL4597010

SCHEMBL4597010

Cc1cc(Br)ncc1C=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
GRIA4 P48058 1/20 0.37
ALDH1A1 P00352 5/20 0.35
TSHR P16473 1/20 0.35
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
LMNA P02545 2/20 0.35
ERN1 O75460 4/20 0.34
PRKDC P78527 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
MPI P34949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7993654 0.78 LMNA (0.41) ALDH1A1TRIM24TRIM33LMNAERN1
SCHEMBL29954921 0.78 UHRF1 (0.46) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL6631118 0.78 UHRF1 (0.46) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL29955122 0.77 GRIA1 (0.38) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL29953846 0.76 NNMT (0.50) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL587068 0.76 NNMT (0.50) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL9939745 0.75 ERN1 (0.35) TRIM24TRIM33LMNAERN1PRKDC
SCHEMBL15873128 0.75 TRIM24 (0.35) TRIM24TRIM33LMNAERN1PRKDC
SCHEMBL29790188 0.75 TRIM24 (0.35) TRIM24TRIM33LMNAERN1PRKDC
SCHEMBL16333251 0.75 TDP1 (0.42) ALDH1A1TRIM24TRIM33LMNAERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
US-12503468-B2 Heterocyclic compound, intermediate, preparation method therefor and application thereof WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2025-12-23 US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 WO disclosed
US-20240034729-A9 HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2024-02-01 US disclosed
EP-3826721-B1 NAPHTHYRIDINE COMPOUNDS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2023-10-11 EP disclosed
US-11780834-B2 Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use GENENTECH, INC. (US) 2023-10-10 US disclosed
US-20230068538-A1 HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) 2023-03-02 US disclosed
WO-2022266162-A1 AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2022-12-22 WO disclosed
CN-111377917-B Heterocyclic compound, intermediate, preparation method and application thereof 武汉朗来科技发展有限公司 2022-12-06 CN disclosed
EP-3889154-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-10-06 EP disclosed
US-20210277024-A1 NAPHTHYRIDINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2021-09-09 US disclosed
WO-2020135771-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 武汉朗来科技发展有限公司 2020-07-02 WO disclosed
WO-2020023551-A1 NAPHTHYRIDINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-01-30 WO disclosed
CN-101309690-A Chemokine receptor binding compounds ANORMED INC (CA) 2008-11-19 CN disclosed
EP-1924265-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS Genzyme Corporation (US) 2008-05-28 EP disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
WO-2007022371-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2007-02-22 WO disclosed
WO-2007022371-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230068538-A1 HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF P2RX3, P2RX7, P2RX4 GRIA1 1694/4885GRIA2 2628/4885GRIA3 1046/4885
US-12503468-B2 Heterocyclic compound, intermediate, preparation method therefor and application thereof P2RX3, P2RX7, P2RX4 GRIA1 1694/4885GRIA2 2628/4885GRIA3 1046/4885
US-20210277024-A1 NAPHTHYRIDINE COMPOUNDS AND USES THEREOF NEK1, NEK11, NEK5 GRIA1 2739/4885GRIA2 3694/4885GRIA3 3766/4885
US-20240034729-A9 HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF P2RX3, P2RX7, P2RX4 GRIA1 1694/4885GRIA2 2628/4885GRIA3 1046/4885
US-20070066624-A1 Chemokine receptor binding compounds CCR5, CCR4, CCR1 GRIA1 833/4885GRIA2 1348/4885GRIA3 875/4885
US-11780834-B2 Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use TP53, DPYD, FLI1 GRIA1 3104/4885GRIA2 3400/4885GRIA3 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.